Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.63 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7654214 | 1.00 | NFE2L2 (0.63) | NFE2L2CNR2PABPC1RAB9AEIF4H | |
| SCHEMBL7655780 | 1.00 | NFE2L2 (0.63) | NFE2L2CNR2PABPC1RAB9AEIF4H | |
| SCHEMBL10624527 | 0.82 | TUBB1 (0.49) | NFE2L2CNR2CYP3A4ATMPTGS2 | |
| SCHEMBL12506745 | 0.82 | TUBB1 (0.49) | NFE2L2CNR2CYP3A4ATMPTGS2 | |
| SCHEMBL16953105 | 0.82 | NFE2L2 (0.48) | NFE2L2CNR2CYP3A4ATMPTGS2 | |
| SCHEMBL24697613 | 0.80 | ALDH1A1 (0.46) | NFE2L2CNR2CYP3A4ATMTYR | |
| SCHEMBL11599639 | 0.80 | CNR2 (0.64) | NFE2L2CNR2RAB9ACYP3A4ATM | |
| SCHEMBL2660226 | 0.80 | VCP (0.56) | NFE2L2CNR2RAB9ACYP3A4ATM | |
| SCHEMBL15232822 | 0.80 | CNR2 (0.44) | NFE2L2CNR2CYP3A4ATMTYR | |
| SCHEMBL2660229 | 0.80 | VCP (0.56) | NFE2L2CNR2RAB9ACYP3A4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177485-A1 | CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-6372911-B1 | REACTING COMPOUND CONTAINING AT LEAST ONE CARBON-CARBON DOUBLE BOND WITH CARBAMATE IN AQUEOUS SOLVENT IN PRESENCE OF BASE, OSMIUM CATALYST, CO-OXIDANT, AND OPTIONALLY ASYMMETRIC LIGAND, TO FORM REACTION MIXTURE CONTAINING BETA-HYDROXY CARBAMATE | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | NFE2L2 3735/4885CNR2 3455/4885PABPC1 3009/4885 |
| US-20220177485-A1 | CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, WASF2, WEE2 | NFE2L2 323/4885CNR2 4458/4885PABPC1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.